Synovus Financial Corp Boosts Stake in Haleon plc (NYSE:HLN)

Synovus Financial Corp raised its position in shares of Haleon plc (NYSE:HLN) by 5.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 156,467 shares of the company’s stock after purchasing an additional 7,633 shares during the quarter. Synovus Financial Corp’s holdings in Haleon were worth $1,493,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Jane Street Group LLC grew its holdings in shares of Haleon by 1,689.4% in the third quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after purchasing an additional 250,169 shares in the last quarter. Toronto Dominion Bank grew its stake in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after buying an additional 3,470 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in shares of Haleon by 25.0% in the 3rd quarter. Sanctuary Advisors LLC now owns 245,310 shares of the company’s stock worth $2,367,000 after buying an additional 49,064 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Haleon during the 3rd quarter valued at about $203,000. Finally, Peapack Gladstone Financial Corp lifted its holdings in shares of Haleon by 3.2% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock valued at $474,000 after acquiring an additional 1,390 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HLN. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. HSBC reaffirmed a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.95.

Haleon Stock Performance

Shares of Haleon stock opened at $10.13 on Wednesday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock’s fifty day moving average is $10.06 and its two-hundred day moving average is $9.81. Haleon plc has a 52 week low of $8.04 and a 52 week high of $10.80. The company has a market capitalization of $45.76 billion, a PE ratio of 29.79, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. As a group, analysts expect that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. This is an increase from Haleon’s previous — dividend of $0.05. Haleon’s payout ratio is currently 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.